Summer 2027

Data Scientist Co-op

Posted on 8/20/2026

Deadline 9/18/26
Philips

Philips

Manufactures sleep therapy and respiratory devices

Compensation Overview

$33 - $48/hr

+ Overtime eligible

No H1B Sponsorship

Plymouth, MN, USA

Hybrid

Office-based role requiring at least 3 days on-site per week; candidates must reside in or within commuting distance of Plymouth.

Master's, PhD

Category
Data & Analytics (1)
Required Skills
Data Science
TensorFlow
Neural Networks
PyTorch
Machine Learning
Data Analysis
Requirements
  • Pursuing a master's degree or doctorate in computer science, computer engineering, or a related field.
  • Experience working with deep learning frameworks such as PyTorch and TensorFlow and convolutional neural networks such as U-Net and ResUNet.
  • Strong understanding of medical imaging standards and formats such as DICOM and NIfTI.
  • Familiarity with imaging data management tools such as PACS and cloud-based storage for imaging data.
  • Experience managing medical imaging databases and understanding how imaging data is used in artificial intelligence and machine learning model development.
  • Ability to perform problem solving and debugging.
  • Ability to work on-site at the Plymouth, Minnesota site.
  • Ability to successfully perform the position's minimum physical, cognitive, and environmental requirements with or without accommodation.
Responsibilities
  • Work with a member of the Software and Artificial Intelligence/Machine Learning Engineering team on a focused project that can be completed during the co-op.
  • Gather, process, organize, and analyze raw data from different sources, with a focus on clinical imaging or healthcare-related datasets.
  • Perform exploratory data analysis to identify patterns, trends, data quality issues, unexpected results, or preprocessing concerns.
  • Verify the quality, consistency, and reliability of data sources used for artificial intelligence and machine learning model development and validation.
  • Document data sources, data-cleaning processes, exploratory analysis, assumptions, parameters, and performance metrics.
  • Assist data scientists and machine learning engineers with model training, evaluation, tuning, and performance analysis under the guidance of experienced team members.
  • Complete required training for regulatory requirements and quality management system standards.
  • Create and present an end-of-summer intern presentation summarizing the project, technical approach, results, learnings, and impact.
Desired Qualifications
  • Technical writing and presentation skills.
  • Communication and teamwork skills.

Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.

Company Size

N/A

Company Stage

Acquired

Total Funding

$164.7M

Headquarters

Murrysville, Pennsylvania

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Philips reported EUR 17.8 billion 2025 sales and returned to EUR 897 million net income.
  • Q1 2026 orders grew 6%, while Philips reiterated 3%-4.5% sales growth and EUR 1.3-1.5 billion cash.
  • Ventilator remediation continues in 2026, and 31 countries already closed field-safety actions.

What critics are saying

  • The FDA still bars new U.S. CPAP, BiPAP, and respiratory-device sales until compliance.
  • June 2025 DreamStation recall shows supplier rework failures still trigger fresh safety interruptions.
  • Respironics-related charges reached EUR 209 million in 2025, and DOJ investigations remain excluded from guidance.

What makes Philips unique

  • Philips Respironics remains one of few global sleep-therapy platforms with installed-device service scale.
  • Its 2026 FDA consent decree preserves accessories, consumables, parts, and medically necessary-device sales.
  • More than 99% of recalled CPAP and BiPAP devices were remediated globally by December 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.